Day One Bio Day One Bio

Scientific Publications

Contributing to and advancing the scientific dialogue.

September 2024

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification.

Vieito M, Garralda Cabanas E, Mehmi I, Gaudy-Marqueste C, O’Neil BH, Medina TM, Body Arance A, Kummar S, Najjar YG, Bedard PL, Chu C, McKenna C, Hume S, Kopp LM, Lee J. 614MO – Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification. Mini oral presentation at: ESMO Congress 2024; September 14, 2024; Barcelona, Spain.

June 2024

Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.

Kline C, Waanders AJ, Ziegler DS, Kilburn LB, Nysom K, van der Lugt J, Hassall TE, Gerber NU, Segal D, Larouche V, Khuong-Quang D-A, Hansford JR, Leary SES, Hernáiz Driever P, Bailey S, Perreault S, McCowage G, Witt O, Baxter PA, Kang HJ, Han JW, Hargrave D, Franson AT, Yalon Oren M, Toledano H, Abdelbaki MS, Jabado N, Gottardo NG, Whipple NS, Chi, Oren L, Tan EEK, Mueller S, Wright KD, Blackman SC, Qiu J, Podesta D, Walter A, Da Costa D, Manley P, McLeod L, Landi DB. LGG-40. Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial. Oral presentation at: 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024); June 30, 2024; Philadelphia, PA.

June 2024

Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial

Kline C, Waanders AJ, Ziegler DS, Kilburn LB, Nysom K, van der Lugt J, Hassall TE, Gerber NU, Segal D, Larouche V, Mueller S, Walter A, Manley P, McLeod L, Landi DB. Abstract 10036. Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial. Poster presentation at: 2024 ASCO (American Society for Clinical Oncology) Annual Meeting; June 1, 2024; Chicago, IL & Virtual.

April 2024

Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records

Zelt S, Cooney T, Yu S, Daral S, Krebs B, Markan R, Manley P, Kieran M, Govinda Raju S. Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records [published online ahead of print April 27, 2024]. Neuro-Oncol Pract. 2024.

April 2024

Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation

Rastogi S, Perino S, Lal-Nag M, Wang Y, Blackman SC, Venetsanakos E. 1972. Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2024; April 8, 2023; San Diego, CA.

April 2024

Clinical activity and safety of tovorafenib in patients with optic pathway gliomas in FIREFLY-1

Leary SES, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang D-A, Gottardo HG, Hassall T, Han JW, Yalon Oren M, Chi SN, McLeod L, Qiu J, McKenna C, Da Costa D, Govinda Raju S, Hargrave D, Kilburn LB, Landi DB, Nysom K. 902. Clinical Activity and Safety of Tovorafenib in Patients with Optic Pathway Gliomas in FIREFLY-1. Poster presentation at: 2024 ASPHO (American Society of Pediatric Hematology/Oncology); April 4 & 5, 2024; Seattle, WA.

Jan 2024

A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martínez O, Zápotocký M, Scheinemann K, Schouten-van Meeteren AYN, Sehested A, Opocher E, Hernáiz Driever P, Avula S, Ziegler DS, Capper D, Koch A, Sahm F, Qiu J, Tsao L-P, Blackman SC, Manley P, Milde T, Witt R, Jones DTW, Hargrave D, Witt O. LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration [published online ahead of print January 30, 2024]. BMC Cancer. 2024.

Nov 2023

Clinical activity of RAF inhibitor tovorafenib according to prior MAPK inhibitor treatment in the registrational low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study

Khuong-Quang DA, Nysom K, Landi DB, Ziegler DS, Hernáiz Driever P, Leary SES, Bailey S, van der Lugt J, Perreault S, Waanders AJ, Baxter PA, Witt O, Hargrave D, McCowage G, Hansford JR, Toledano H, Oren L, Tan EEK, Gerber NU, Kang HJ, Larouche V, Abdelbaki MS, Cornelio I, Kim Y, Walter A, Manley P, Kilburn LB. CTNI-37. Clinical activity of RAF inhibitor tovorafenib according to prior MAPK inhibitor treatment in the registrational low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. Oral presentation at: 28th Annual Meeting and Education Day of the Society for Neuro-Oncology, November 17, 2023, Vancouver, Canada.

See our progress in motion.

See open jobs

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.

Yes No